H emorrhage accounts for over a third of early trauma deaths (1) and is a leading cause of preventable mortality (2). Up to 25% of severely injured patients arrive at hospital with a significant coagulopathy. Patients presenting with this acute traumatic coagulopathy (ATC) have a mortality approaching 50%, and significantly greater transfusion requirements, organ injury, septic complications, and critical care stay (3-5). Management strategies targeting ATC may allow significant improvement in outcomes (6 -8). These damage control resuscitation approaches require early identification of ATC to allow rapid activation of transfusion protocols. Prediction of ATC from admission clinical parameters is unreliable, while laboratory-based clotting tests have logistic issues, limiting their utility in acute trauma care (9, 10).
H emorrhage accounts for over a third of early trauma deaths (1) and is a leading cause of preventable mortality (2) . Up to 25% of severely injured patients arrive at hospital with a significant coagulopathy. Patients presenting with this acute traumatic coagulopathy (ATC) have a mortality approaching 50%, and significantly greater transfusion requirements, organ injury, septic complications, and critical care stay (3) (4) (5) . Management strategies targeting ATC may allow significant improvement in outcomes (6 -8) . These damage control resuscitation approaches require early identification of ATC to allow rapid activation of transfusion protocols. Prediction of ATC from admission clinical parameters is unreliable, while laboratory-based clotting tests have logistic issues, limiting their utility in acute trauma care (9, 10) .
In the absence of a rapid diagnostic tool, current ATC management relies on empirical transfusion strategies activated on the basis of clinical surrogates or physician gestalt (11) (12) (13) . This results in delayed correction of ATC and is associated with suboptimal blood product usage (14, 15) . Inadequate transfusion is associated with poor outcomes (12) , but overtransfusion results in additional donor exposure and is wasteful of a precious resource. The need for an accurate modality to rapidly diagnose ATC has prompted a renewed interest Objective: To identify an appropriate diagnostic tool for the early diagnosis of acute traumatic coagulopathy and validate this modality through prediction of transfusion requirements in trauma hemorrhage.
Design: Prospective observational cohort study. Setting: Level 1 trauma center. Patients: Adult trauma patients who met the local criteria for full trauma team activation. Exclusion criteria included emergency department arrival >2 hrs after injury, >2000 mL of intravenous fluid before emergency department arrival, or transfer from another hospital.
Interventions: None.
Measurements: Blood was collected on arrival in the emergency department and analyzed with laboratory prothrombin time, point-of-care prothrombin time, and rotational thromboelastometry. Prothrombin time ratio was calculated and acute traumatic coagulopathy defined as laboratory prothrombin time ratio >1.2. Transfusion requirements were recorded for the first 12 hrs following admission.
Main Results: Three hundred patients were included in the study. Laboratory prothrombin time results were available at a median of 78 (62-103) mins. Point-of-care prothrombin time ratio had reduced agreement with laboratory prothrombin time ratio in patients with acute traumatic coagulopathy, with 29% falsenegative results. In acute traumatic coagulopathy, the rotational thromboelastometry clot amplitude at 5 mins was diminished by 42%, and this persisted throughout clot maturation. Rotational thromboelastometry clotting time was not significantly prolonged. Clot amplitude at a 5-min threshold of <35 mm had a detection rate of 77% for acute traumatic coagulopathy with a false-positive rate of 13%. Patients with clot amplitude at 5 mins <35 mm were more likely to receive red cell (46% vs. 17%, p < .001) and plasma (37% vs. 11%, p < .001) transfusions. The clot amplitude at 5 mins could identify patients who would require massive transfusion (detection rate of 71%, vs. 43% for prothrombin time ratio >1.2, p < .001).
Conclusions: In trauma hemorrhage, prothrombin time ratio is not rapidly available from the laboratory and point-of-care devices can be inaccurate. Acute traumatic coagulopathy is functionally characterized by a reduction in clot strength. With a threshold of clot amplitude at 5 mins of <35 mm, rotational thromboelastometry can identify acute traumatic coagulopathy at 5 mins and predict the need for massive transfusion. (Crit Care Med 2011; 39:2652-2658) KEY WORDS: coagulopathy; diagnosis; hemorrhage; rotational thromboelastometry; transfusion; trauma in viscoelastic coagulation tests. These functional tests, such as rotational thromboelastometry (ROTEM -Pentapharm, Munich, Germany) and thromboelastography (Hemoscope, Niles, IL), analyze whole blood and evaluate all stages of secondary hemostasis (16) . The clinical application of this technology to guide blood replacement has been widely used in liver transplantation (17) , cardiac surgery (18, 19) , and emergency vascular procedures (20) . Emerging evidence suggests that ROTEM may have diagnostic capability in ATC (21) and could potentially direct transfusion therapy in trauma hemorrhage (22, 23).
The overall objective of the study was to identify an appropriate diagnostic tool for the early diagnosis of ATC. The first aim of the study was to evaluate point-ofcare (PoC) prothrombin time (PT) as an alternative to the laboratory measurement of clotting times. The second aim was to determine the thromboelastometry profile of ATC. Third, we aimed to identify a rapidly available parameter for the identification of patients with ATC. Lastly, we wished to validate this threshold by its ability to predict transfusion requirements in trauma hemorrhage.
MATERIALS AND METHODS

Study Design
This was a single-center, prospective, cohort study of trauma patients presenting directly to a Level 1 trauma center between January 2007 and June 2009. The study was reviewed and approved by the U.K. National Research Ethics Committee. We analyzed baseline laboratory coagulation parameters on arrival for comparison with PoC PT, ROTEM, and base deficit.
Setting
Major urban trauma center with over 1400 trauma team activations per year, of which 25% are severely injured with an injury severity score Ͼ15. Penetrating trauma accounts for 21% of workload.
Massive Hemorrhage Protocol
Activation of the massive hemorrhage protocol was on the basis of clinical markers of shock (systolic blood pressure Ͻ90 mm Hg, poor response to initial fluid infusion, and suspicion of ongoing hemorrhage) and provided immediate access to emergency packed red blood cell (PRBC) units. Fresh frozen plasma was subsequently provided with PRBCs with the aim of delivering a 2:3 ratio. Platelets and cryoprecipitate were automatically administered after the first four units of fresh frozen plasma if hemorrhage was ongoing. In the acute bleeding phase, transfusion was not guided by laboratory markers.
Patient Selection
All adult trauma patients (Ͼ15 yrs) who met the local criteria for full trauma team activation were eligible for enrollment and recruited into the study when research personnel were present (08:00 -20:00 daily). Exclusion criteria were: arrival in the emergency department Ͼ2 hrs after injury; the administration of Ͼ2000 mL of intravenous fluid before emergency department arrival; transfer from another hospital; and burns covering Ͼ5% of the total body surface area. Patients were retrospectively excluded if they declined to give consent to use research samples collected, were found to be taking anticoagulant medications, had moderate or severe liver disease, or a known bleeding diathesis.
Sampling Technique
A 20-mL research sample of blood was drawn from either the femoral vein or antecubital fossa along with the standard trauma laboratory tests within 20 mins of arrival in the emergency department. Blood for ROTEM analysis was drawn into a 2.7-mL citrated vacutainer (0.109 M buffered sodium citrate, 3.2%; Becton Dickinson, Plymouth, UK) and processed in the trauma research laboratory. Samples for PT, partial thromboplastin time, and fibrinogen were collected into 4.5-mL glass vacutainers (0.109 M buffered sodium citrate, 3.2%; Becton Dickinson, Plymouth, UK) for standard processing by the central hospital laboratory along with a standard full blood count. PoC PT analysis was performed using a CoaguChek XS device (Roche Diagnostics Ltd, Burgess Hill, UK). PT ratio (PTr) was calculated as observed PT divided by mean control PT for both laboratory and PoC PT values to enable direct comparison. Arterial blood analysis for base deficit was performed simultaneously with the research sample collection.
ROTEM Analysis
Samples were processed within 1 hr of blood draw at 37°C on a ROTEM ␦ instrument (Pentapharm GmbH, Munich, Germany), and all treating clinicians were blinded to the results. The methodology and the parameters of ROTEM have previously been described in detail (16) . Twenty microliters of recalcitrant (STARTEM) and 20 L of tissue factor derived from rabbit brain (EXTEM) were placed into the test cuvette, after which 300 L of the blood sample was added. Activation with tissue factor was performed to standardize the in vitro coagulation process and produce a more rapid result. All pipetting steps and the mixing of reagents with samples were performed as standard using the automated electronic pipette program. Clotting time, ␣ angle, clotformation time, clot amplitude at 5 mins (CA5), and maximum clot firmness were reported for each sample analyzed.
Data Collection and Analysis
Data were collected prospectively on patient demographics, time of injury, mechanism (blunt or penetrating), prehospital fluid administration, time of arrival in the emergency department, baseline vital signs, and total transfusion requirements in the first 12 hrs of admission. Injury was classified using the injury severity score as severe (Ͼ15) or uninjured (Ͻ5) (24). Hypoperfusion was defined as base deficit Ͼ6 mEq/L (25, 26). Massive transfusion was defined as a requirement of ten or more units of blood in the first 12 hrs.
ATC was defined as a laboratory PTr Ͼ1.2 (4, 5, 27). In trauma, PTr Ͼ1.2 has been shown to be a clinically relevant threshold associated with significant increases in mortality and transfusion requirements (27). We defined the detection rate as the proportion of patients with ATC that would be positively identified by PoC or ROTEM, and the falsepositive rate as the proportion of patients without ATC that would be incorrectly identified as positive. We determined normal values for ROTEM parameters from patients without ATC (PTr Յ1.2, noncoagulopathic) as mean Ϯ 1 SD. For analysis of ROTEM parameters not directly comparable to the PTr (e.g., clot strength parameters), we also used the pathophysiologic basis of ATC to select a cohort of high-risk patients with a combination of severe injury (injury severity score Ͼ15) and shock (base deficit Ͼ6 mEq/L) (27, 28). Normal quantile plots were used to test for normal distribution. Nonparametric data are expressed as median, interquartile range and analyzed with Mann-Whitney U test. Parametric data are expressed as mean Ϯ 95% confidence intervals. Two-group analysis was performed with a two-tailed unequal variance Student's t test. A Bland-Altman plot was used to test the clinical agreement between PoC and central laboratory PTr results. ROTEM changes over time were analyzed using twoway analysis of variance. To eliminate survivor bias, patients who died within 12 hrs of admission were excluded from analysis of transfusion outcomes. A sensitivity analysis was performed to assess the impact of this methodology on test performance.
RESULTS
There were 325 patients enrolled into the study over the 19-month period. ROTEM sample analysis was incomplete in three patients, consent processes could not be completed in 15 cases, and there were seven retrospective exclusions, leaving 300 patients available for analysis. Clinical characteristics, admission physiology, and laboratory parameters are detailed in Table 1 . Median time from injury to blood sampling was 86 (69 -112) mins. Minimal intravenous fluid was administered before baseline sample collection and no patient received artificial colloid or vasoactive agents before the first blood draw.
Laboratory PT results were available to clinicians via the hospital electronic record system with a median time of 78 (62-103) mins (Fig. 1A) . In only two cases were results available in Ͻ30 mins. Overall, there was good agreement between the PoC and laboratory PTr results, with a mean bias of Ϫ1.4% (Fig. 1B) . However, this agreement was confined to patients without coagulopathy, where 99% of PoC values were within 95% con-fidence intervals. Accuracy was lost in patients with ATC when only 71% of PoC PTr values were in agreement with the laboratory values ( Fig. 1B) . Twenty-nine percent of PoC readings were false negative for ATC, and PoC had an overall ATC detection rate of 71% and a false-positive rate of 2%. Low hematocrit (Ͻ0.30) was associated with larger discrepancies between PoC and laboratory results (vs. 0.3-0.39, p ϭ .05; vs. 0.4 -0.49, p ϭ .04, Fig. 1C ).
Computer-simulated ROTEM graphs averaging data derived from all patients in the study produced a characteristic trace for patients with ATC ( Fig. 2A) . Clot strength was diminished by 42% at 5 mins (CA5 normal vs. ATC, p Ͻ .001) and persisted throughout clot maturation (40% reduction in maximum clot firmness compared to normal, p Ͻ .001, Fig. 2B ). Comparing the two groups, there was complete separation between all clot strength parameters but an overlap in ROTEM clotting times, with only a trend toward prolongation in coagulopathic patients (116 vs. 66 secs, p ϭ .068) ( Table 2 ). Since clot strength is not directly comparable with the PTr, we also analyzed the ROTEM signatures of patients at high risk of ATC (combination of injury and shock). This cohort had significantly lower clot strengths compared to uninjured, nonshocked patients (p Ͻ .001) (Fig. 2C) . The coexistence of shock and injury had a synergistic negative effect on clot strength (22% reduction in CA5; 15% reduction in maximum clot firmness) compared to uninjured patients without shock (Table 3 ). The clotting time was only mildly prolonged in patients with combined injury and shock (Table 3) . ATC is thus characterized by a reduction in clot strength and only minimal changes in clotting times.
Therefore, we examined the potential for ROTEM to detect patients with ATC based on a clot strength parameter. We chose the CA5 since there was good separation of normal and ATC curves at this time point (Fig. 2, B and C) , and set a threshold of CA5 at 35 mm, representing one SD below normal ( Table 2) . Fifty-four patients (18%) had a low CA5 compared to 23 (8%) patients with PTr Ͼ1.2. The CA5 Յ35-mm threshold had a detection rate of 77% for patients with ATC, and a false-positive rate of 13% (Fig. 2D) . For the high-risk cohort (severe injury and shock), 61% of patients had CA5 Յ35 mm compared to 33% with a PTr Ͼ1.2 ( Table 3) .
Average PRBC transfusion requirements for patients with CA5 Յ35 were 4 vs. 1 units (p Ͻ .001) (Fig. 3A) , and this cohort was three times more likely to receive PRBCs (46% vs. 17%, p Ͻ .001).
Patients with low CA5 also had a greater likelihood of receiving fresh frozen plasma (37% vs. 11%, p Ͻ .001), with average plasma transfusion requirements of 2 vs. 0 units (p Ͻ .001) (Fig. 3B) . The CA5 Յ35-mm threshold was able to predict massive transfusion (10ϩ PRBC units) with a detection rate of 71%, compared to 43% for a PTr-based definition of ATC (Table 4) . A sensitivity analysis demonstrated that the inclusion of patients who died within 12 hrs of admission produced only a minimal effect on the accuracy of the model (73% detection rate for 10ϩ PRBC units). Nearly 60% of patients requiring massive transfusion had a normal PTr, but only 30% had a normal CA5 (Fig. 3, C and D) . Overall, CA5 Ͼ35 mm had a negative predictive value of 83% for any red cell transfusion, and 99% for massive transfusion (10ϩ units) ( Table  4) , with an area under the curve of 0.803 (95% confidence interval 0.635-0.972).
DISCUSSION
This study is the largest prospective evaluation of diagnostic modalities for ATC to date. We have confirmed that laboratory clotting times are not available within clinically useful timeframes, and that PoC devices that measure PT can be inaccurate in ATC and trauma hemorrhage. ATC has a characteristic thromboelastogram that is characterized by a reduction in clot strength, with much smaller changes in laboratory clotting times. Based on these results, a clot strength parameter derived from the thromboelastometry curve at 5 mins may provide a more clinically relevant definition of ATC, and can more accurately predict the need for massive transfusion than standard clotting tests.
Traditional coagulation screening tests are the basis of current definitions of ATC. PT and activated partial throm-boplastin time, however, do not assess the whole coagulation system and use clot formation as their end point, which occurs when only a limited proportion of all physiologically relevant thrombin is formed. These static tests identify variable reductions in the levels of coagulant factors but may have limited value in managing severe hemorrhage (29 -32) . ATC however, is not thought to be a consumptive coagulopathy, and levels of clotting factors are probably preserved initially (33) . Clotting time, the ROTEM equivalent of PT, is not significantly prolonged in ATC. In the setting of ATC, the PT is the least correlated parameter with ROTEM and provides only partial information on clot initiation, with no information on clot strength, the rate of clot propagation, or clot lysis. Based on the evidence from this study and others, it appears that both laboratory and PoC PT assays are inadequate for the diagnosis of ATC in trauma hemorrhage (34) .
ATC has a thromboelastometry signature profile characterized by slow clot formation and persistently reduced clot strength of around 40%. The low uptake of ROTEM and thromboelastography in clinical practice may be due to perceived difficulties in the interpretation of the viscoelastic clot traces. We have shown that a reliable and clinically important diagnostic reading can be made after 5 mins using a single parameter. A CA5 Յ35-mm threshold identifies more coagulopathic patients than PTr 1.2, and we found this ROTEM definition to be more sensitive than PTr for predicting the need for massive transfusion. This finding is supported by a previous study of 44 combat casualties, which found that thromboelastography maximum amplitude within the first 24 hrs was a better predictor of transfusion than conventional clotting tests (35) . All ROTEM parameters had negative predictive values approaching 100% for massive transfusion. A normal ROTEM trace may allow timely termination of massive hemorrhage protocols and preservation of blood stocks.
This study has several limitations. First, samples were only collected at a single time point on arrival, and serial sampling during initial resuscitation may have yielded higher diagnostic accuracy and predictive power. Secondly, a single PoC device was evaluated, and the inaccuracies at high PT values may not translate to other technologies. Thirdly, the aim of the study was to examine ATC and not multifactorial pathology of traumainduced coagulation. This study only focused on the measurement of a hypocoagulable state in bleeding patients, and we did not attempt to examine hyperfibrinolysis, which is an important component of ATC (36, 37) . The new definition of ATC may therefore not be a definition of trauma-induced coagulation and applicable to patients with longer prehospital 
CONCLUSIONS
Conventional clotting screening assays, whether laboratory-based or PoC, have significant limitations restricting their utility in trauma hemorrhage. ATC is primarily characterized by a reduction in clot strength and has a specific thromboelastometry signature, which can be diagnosed by the CA5. ROTEM can rapidly identify patients who are likely to require massive transfusion. Prospective evaluation is required to assess whether ROTEM can be used to activate massive hemorrhage protocols and guide transfusion therapy. nosis PTr, prothrombin time ratio; CA5, clot amplitude at 5 mins; CT, clotting time. Detection rate (Sensitivity); False-positive rate (1-Specificity). Performance of coagulation parameters for the prediction of packed red blood cell, massive transfusion (ten or more units), and fresh frozen plasma transfusion using laboratory PTr and rotational thromboelastometry.
